While statins are the gold standard for managing cholesterol and cardiovascular risk, a recent study suggests they may have an unexpected relationship with your dental health—specifically regarding periodontitis and alveolar bone loss.
A new study published in Medicina, titled “Changes in Dickkopf-1, but Not Sclerostin, in Gingival Crevicular Fluid Are Associated with Peroral Statin Treatment in Patients with Periodontitis,” examined how peroral statins influence the Wnt signaling pathway…
The Wnt Pathway: A Key to Bone Health
The body maintains bone through a balance of formation and resorption. The Wingless-type (Wnt) signaling pathway is central to this process. However, this pathway can be “turned off” by certain inhibitors:
- Dickkopf-1 (DKK-1): An inhibitor associated with bone resorption.
- Sclerostin (SOST): A glycoprotein that suppresses bone formation.
In periodontitis, these inhibitors are often up-regulated, leading to the destruction of the supporting structures of the teeth.
Study Findings: Statins and DKK-1
Researchers compared 39 patients on statin therapy (the SP group) with 40 patients not taking statins (the P group). They analyzed Gingival Crevicular Fluid (GCF) —an inflammatory exudate found between the tooth and gums—to measure these inhibitors.
The results revealed a significant association between statin use and oral health markers:
- Elevated DKK-1: Patients on statins had significantly higher levels of DKK-1 in their GCF compared to the control group (p=0.04).
- Worse Clinical Parameters: The statin group showed significantly higher Probing Depth (PD) , Gingival Recession (GR) , and Clinical Attachment Loss (CAL).
- Direct Correlation: There was a positive relationship between DKK-1 levels and probing depth; the deeper the periodontal pocket, the higher the DKK-1 concentration ($rho=0.350$).
Summary of Clinical Differences
| Parameter | Periodontitis Only (Median) | Periodontitis + Statins (Median) | p-value |
|---|---|---|---|
| Probing Depth (mm) | 5 | 6 | 0.001 |
| Gingival Recession (mm) | 2 | 3 | 0.03 |
| DKK-1 (pg/mL) | 4.71 | 5.84 | 0.04 |
The Catch: Complexity and Comorbidities
While the data shows higher DKK-1 and worse periodontal markers in statin users, the researchers noted several important caveats:
“Statins did not decrease DKK-1 levels, probably due to the presence of more patients with a higher grade of disease and diabetes in the [statin] group.”
The statin group was generally older (62 vs. 54 years) and had a higher prevalence of diabetes mellitus (21% vs. 3%), both of which are known to accelerate the progression of periodontitis. Furthermore, statins themselves have been associated in some studies with an increased risk of developing diabetes.
Conclusion
The study concludes that peroral statins are associated with GCF levels of DKK-1 , but not sclerostin. While statins are often praised for their systemic anti-inflammatory effects, their impact on the specific inhibitors of bone formation in the mouth may be more complex than previously thought.
For those on long-term statin therapy, these findings highlight the importance of rigorous periodontal monitoring, as the medication may be linked to markers of advanced bone resorption in the jaw.